Tiludronic acid
Alternative Names: Cl-TMBP; ME 3737; Skelid; SR 41319; SR 41319B; Tiludronate; Tiludronate sodiumLatest Information Update: 17 Mar 2009
At a glance
- Originator sanofi-aventis
- Developer Meiji Seika Kaisha; Meiji Seika Pharma; Sanofi; Sanofi Winthrop
- Class Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies
- Mechanism of Action Bone resorption factor inhibitors; Osteoclast inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Osteitis deformans
- Discontinued Postmenopausal osteoporosis; Rheumatoid arthritis
Most Recent Events
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 27 Aug 1999 Sanofi and Synthélabo have merged to form Sanofi-Synthélabo
- 12 Jun 1998 Launched for Osteitis deformans in Spain (PO)